Challenging Times for European Biotech IPOs

Through the first week of May, 2005, five biotechs listed on Europe's main markets. Like their counterparts in the US, these companies have had to deal with difficult public markets and have on the whole raised much less money than they originally intended.

European private investors are faring no better than their US counterparts when it comes to IPOs in 2005. Both sides of the Atlantic have been plagued by problematic public markets that have resulted in public offerings at or below estimated pricing ranges and difficult aftermarket environments. (See Exhibit 1.) So far this year five firms have hit Europe's main markets: Ardana Bioscience Ltd. on the London Stock Exchange [See Deal], Intercell AG in Vienna [See Deal], Paion AG in Frankfurt [See Deal], Arpida Ltd. on the Swiss Exchange [See Deal], and, most recently as of START-UP press time, Galapagos Genomics NV in Amsterdam and Brussels [See Deal]. Much like in the US, others including Scotland's Cyclacel Ltd. , have gotten cold feet and pulled their offerings [See Deal].

While US companies have traditionally enjoyed public market support unavailable to European companies, those days are seemingly gone. The wave...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By 

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Business

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By 

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.